Uveitis Drugs

Uveitis Drugs

Global Uveitis Drugs Market to Reach US$1.2 Billion by 2030

The global market for Uveitis Drugs estimated at US$888.6 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. Corticosteroid Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$469.0 Million by the end of the analysis period. Growth in the Cycloplegic Agents segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$242.1 Million While China is Forecast to Grow at 7.8% CAGR

The Uveitis Drugs market in the U.S. is estimated at US$242.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$251.8 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Uveitis Drugs Market - Key Drivers and Trends Summarized

 

Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye, which includes the iris, ciliary body, and choroid. This condition can lead to severe complications, including vision loss if left untreated. Uveitis can be caused by infections, autoimmune disorders, or exposure to toxins, and its symptoms range from eye redness and pain to blurred vision. The primary goal of uveitis treatment is to reduce inflammation, manage pain, and prevent further tissue damage. The drugs used for treating uveitis include corticosteroids, immunosuppressants, biologics, and nonsteroidal anti-inflammatory drugs (NSAIDs).

The uveitis drugs market has witnessed significant advancements and diversification over recent years. Traditional treatments like corticosteroids remain the mainstay for managing acute inflammation due to their potent anti-inflammatory properties. However, long-term use of steroids can lead to adverse effects, prompting the development of alternative therapies. Immunosuppressants, such as methotrexate and cyclosporine, are increasingly used for chronic cases to modulate the immune response. Furthermore, the advent of biologics, including TNF inhibitors like adalimumab, has revolutionized the treatment landscape by offering targeted action with fewer systemic side effects. These biologics are particularly beneficial for patients with refractory uveitis or those who cannot tolerate conventional treatments. Additionally, novel drug delivery systems, such as intravitreal injections and sustained-release implants, have improved the efficacy and convenience of uveitis management.

The growth in the uveitis drugs market is driven by several factors. Firstly, the increasing prevalence of autoimmune disorders and infectious diseases, which are major risk factors for uveitis, has escalated the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceuticals have led to the development of innovative biologics and targeted therapies, enhancing treatment options for patients. Additionally, the rising awareness and diagnosis of uveitis have resulted in earlier and more aggressive treatment approaches, further boosting market demand. The expansion of healthcare infrastructure in emerging markets has also improved access to uveitis treatments, contributing to market growth. Furthermore, strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of new drugs and therapies. Lastly, regulatory support and expedited approval processes for orphan drugs and treatments for rare diseases like uveitis are encouraging innovation and investment in this field.

Select Competitors (Total 74 Featured) -

• AbbVie, Inc.
• AdvaCare Pharma
• Alcon, Inc.
• Alimera Science Inc.
• Bausch + Lomb Corporation
• Clearside Biomedical inc.
• Fera Pharmaceuticals
• Kiora Pharmaceuticals, Inc.
• Kubota Pharmaceutical Holdings Co., Ltd.
• Merck & Co. Inc.
• Novartis International AG
• Palatin Technologies, Inc.
• Pfizer Inc.
• Santen Pharmaceutical Co., Ltd
• Tarsier Pharma Ltd;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.